Clinical Research Directory
Browse clinical research sites, groups, and studies.
Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
Sponsor: Fujian Medical University
Summary
This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as short-term surgical outcomes and long-term prognosis.
Official title: Biochemical, Radiological and Pathological Responses to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: A Multicenter Study
Key Details
Gender
All
Age Range
14 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
120
Start Date
2025-12-23
Completion Date
2029-06-30
Last Updated
2026-02-19
Healthy Volunteers
No
Conditions
Interventions
Multitarget Tyrosine Kinase Inhibitors
Patients with or without actionable genomic alterations may receive a multikinase inhibitor (e.g., lenvatinib or anlotinib) as neoadjuvant therapy.
BRAF inhibitor dabrafenib and MEK inhibitor trametinib
Patients with BRAF V600E mutation may receive combination therapy with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib.
RET Inhibitor
Patients with RET fusion may receive a selective RET inhibitor (e.g., selpercatinib).
PD(L)-1 inhibitor
In selected cases, combination regimens incorporating immunotherapy may be considered.
Biopsy
While fine-needle aspiration (FNA) is the standard initial diagnostic modality for thyroid nodules, core needle biopsy (CNB) is performed to obtain tissue cores for histological subtyping and molecular profiling in locally advanced cases.
Surgery
Patients considered resectable after neoadjuvant therapy will undergo definitive surgery, as determined by consensus of the multidisciplinary team (MDT).
Surgery
Patients deemed resectable at baseline will undergo immediate surgery based on MDT consensus and informed patient preference.
Locations (1)
Fujian Medical University Union Hospital
Fuzhou, Fujian, China